Purchase Order 36C25026P0251
Award Date 12/29/25
Potential Completion Date 12/28/26
Potential Value $244K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Cleveland, OH 44106, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Service Contract Act
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Veterans Affairs, Veterans Integrated Service Network 1 (VISN 1) awarded a contract call to Adaptive Biotechnologies Corporation valued at $5,850.00 for ClonoSEQ testing services, with an ultimate completion date of July 14, 2025. This award is issued as a Blanket Purchase Agreement (BPA) call under Adaptive's existing single-award BPA with VISN 1, valued at $828,750 with a five-year ordering period through July 2027. The contract utilizes firm fixed-price pricing with no...
- The Department of Veterans Affairs, Veterans Integrated Service Network 1 (VISN 1) awarded a firm fixed-price call order valued at $11,700 to Adaptive Biotechnologies Corporation for ClonoSEQ testing services. This award, dated July 15, 2024, represents a call against Adaptive's existing Blanket Purchase Agreement (BPA) with VISN 1, which carries a total ceiling value of $828,750 over a five-year period ending in July 2027. The work will be performed at the VA Medical Center in West Roxbury,...
- This is a firm fixed price contract awarded by the Department of Veterans Affairs (VA) to Adaptive Biotechnologies Corporation, doing business as Adaptive, for ClonoSEQ minimal residual disease testing services. The contract, with a ceiling value of $9,750.00, is a call under a $828,750.00 single award blanket purchase agreement held by Adaptive with the VA's Veterans Integrated Service Network 1 for a 5-year ordering period ending in July 2027. The contract supports VA medical facilities in the...
- This is a firm fixed price Blanket Purchase Agreement (BPA) call awarded by the Department of Veterans Affairs (VA) to Adaptive Biotechnologies Corporation, doing business as Adaptive, to provide ClonoSEQ minimal residual disease testing services for the Boston and West Haven VA health care systems. The contract has a ceiling value of $95,000.00 and a period of performance through July 2026. Adaptive Biotechnologies is a commercial provider of immune-driven medicine services and products, and...
- This is a firm fixed price Blanket Purchase Agreement (BPA) call awarded by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 1 (VISN 1) to Adaptive Biotechnologies Corporation, doing business as Adaptive, for ClonoSEQ minimal residual disease testing services. The $9,750 contract call has a performance period through July 2023 and is part of a larger $828,750 single award BPA for ClonoSEQ services benefiting VA medical facilities in the New England region. The BPA...
- This federal contract award was made by the Defense Health Agency to Adaptive Biotechnologies Corporation, a commercial provider of immune-driven medicine services and products based in Seattle, Washington. The $224,250 firm fixed-price purchase order is for Adaptive's ClonoSEQ in-vitro diagnostic test service that has received Food and Drug Administration clearance for detecting blood cancer in patients. The contract has a period of performance through February 27, 2030 and is not set aside for...
- The Defense Health Agency awarded a definitive firm fixed-price contract to Adaptive Biotechnologies Corporation valued at $681.3K for ClonoSEQ FDA-cleared in vitro diagnostic (IVD) testing services. The contract, awarded on March 14, 2025, runs through March 13, 2030, with performance taking place in San Antonio, Texas. This award represents an open competition with no set-aside designation and reflects the Defense Health Agency's procurement of specialized minimal residual disease testing...
- This is a $385,920 firm fixed price definitive contract awarded by the Defense Health Agency to Adaptive Biotechnologies Corporation, doing business as Adaptive, to provide the ClonoSEQ Minimal Residual Disease In-Vitro Diagnostic Array for the Department of Pathology at the Walter Reed National Military Medical Center. The contract has a performance period ending on February 28, 2025 and does not have a set-aside designation. Adaptive Biotechnologies is a commercial provider of immune-driven...
- This federal contract award is for IMMUNOSEQ MMTCRB SERVICE (DEEP), catalog # ISS20001, with a quantity of 16, awarded to Adaptive Biotechnologies Corporation by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the National Institutes of Health (NIH). The contract has a firm fixed price of $16,560.00 and a completion date of July 31, 2025. This is not a set-aside contract. Adaptive Biotechnologies is a for-profit organization that specializes in...
- The U.S. Defense Health Agency (DHA) has awarded a $76,200 firm fixed price purchase order to Adaptive Biotechnologies Corporation, doing business as Adaptive, for adaptive immunosequencing services. The award does not have a set-aside designation. Adaptive Biotechnologies is a commercial provider of immune-driven medicine services and products. The company has previously received awards from the Department of Health and Human Services (HHS) and Department of Veterans Affairs (VA) to provide...